Nusano

Nusano is a privately held physics company dedicated to transforming the production of medical radioisotopes, which are essential ingredients in cancer diagnostics and therapies. The company's proprietary ion source technology is smaller and more efficient than existing production methods, enabling significantly higher yields and the simultaneous manufacturing of multiple radioisotopes.

Nusano's breakthrough platform addresses long-standing challenges in the radioisotope market, including technical limitations, supply outages, and waste stream concerns. By stabilizing supply chains and making a wide variety of isotopes available, Nusano aims to support the development of next-generation radiopharmaceuticals and enable advanced cancer treatments.

The company's state-of-the-art production facility, a 190,000 square-foot facility in West Valley City, Utah, is scheduled to open in the first quarter of 2025. This facility will have the capability to produce critical radioisotopes such as non-carrier added lutetium-177 and actinium-225, with the latter expected to be available in the second half of 2025. Nusano's technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development.

In March 2024, Nusano opened the Radiance Lab, a 5,000 square-foot radiochemistry laboratory, to develop and implement radioisotope separation and purification processes in preparation for commercial-scale production. This lab will serve as a collaboration and research space, enabling Nusano to offer world-class quality, processes, and scale to its customers.